Defunct Company
Total Trials
12
As Lead Sponsor
3
As Collaborator
9
Total Enrollment
1,687
NCT02279433
A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b
Phase: Phase 1
Role: Collaborator
Start: Sep 30, 2014
Completion: Mar 31, 2019
NCT04151342
CAnadian CAncers With Rare Molecular Alterations (CARMA) - Basket Real-world Observational Study (BROS)
Phase: N/A
Start: Jan 17, 2020
Completion: Dec 31, 2025
NCT04395677
A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene
Phase: Phase 2
Role: Lead Sponsor
Start: Jul 7, 2020
NCT04617054
Basket Study of AB-106 for the Treatment of Patients With Solid Tumors With NTRK Fusion Gene
Start: Jun 1, 2021
Completion: Dec 31, 2026
NCT05357911
A Study on the Effect of AB-106 on the Pharmacokinetics of Digoxin
Start: Jul 13, 2021
Completion: Dec 3, 2021
NCT05577416
A Study of AB-218 in Patients With IDH1 Mutated Low Grade Glioma
Phase: Early Phase 1
Start: Oct 11, 2022
Completion: Dec 1, 2025
NCT05609929
Study the Effect of Omeprazole on AB-106 Pharmacokinetics
Start: Nov 2, 2022
Completion: Jan 20, 2023
NCT05814536
IDH1 Inhibitor AB-218 in Patients With Advanced IDH1 Mutant Cholangiocarcinoma and Other Solid Tumor
Start: May 6, 2023
Completion: Aug 15, 2024
NCT05303519
Safusidenib Phase 2 Study in IDH1 Mutant Glioma
Start: Jun 5, 2023
Completion: Mar 1, 2028
NCT06564324
A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients
Phase: Phase 3
Start: Nov 27, 2024
Completion: Sep 30, 2030
NCT06984224
Pulsed Direct Current Electrical Stimulation for Treatment of Low Back Pain
Start: Jun 30, 2025
Completion: Mar 31, 2026
NCT06214793
Taletrectinib in Previously Treated Metastatic CDH1-mutated Invasive Lobular Cancer (ILC)
Start: Apr 30, 2026
Completion: Jan 1, 2030